MedLumics, a Madrid, Spain-based medical device company developing an optically-guided real-time ablation catheter system for the treatment of Atrial Fibrillation (AF), closed an upsized EUR 18m (USD 21.7m) financing round.
Kurma Partners joined the round which includes and was initially led by Asabys Partners, along with new investors, VI Partners Swiss Innovation and CDTI Innvierte Economía, and existing investors Andera Partners, Caixa Capital Risc and Innogest Capital II.
Having achieved pre-clinical feasibility in 2020, these proceeds will now enable the company to initiate first in-human regulatory clinical studies and automate scalable product manufacturing.
Led by James Greene, CEO, MedLumics is advancing a optical catheter that displays lesion creation in real-time providing the physician with direct visual confirmation of conduction tissue denaturation.
MedLumics also operates Medlumics Ireland Ltd., a subsidiary and IDA company developing automated optical sensor and packaging processes for high volume manufacture.
The company has also appointed Rich Ferrari as Chairman of the Board of Directors. Mr. Ferrari brings to the team his experience in medical device innovation and commercialization as a CEO of two publicly traded medical technology companies and as co-founder and Managing Director of De Novo Ventures. Current Chairman Olivier Litzka of Andera Partners will assume the role of Vice Chairman.